Jing Jia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jing Jia has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Chunyu Wang
Level Three Laboratory of Traditional Chinese Medicine Preparation of National Administration of Traditional Chinese Medicine, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, 250011, China
1 shared publicationHan Zheng
Department of Orthopedics, The Second Qilu Hospital of Shandong University, Jinan, Shandong, China
1 shared publication- Hao Yin
Department of Pharmacy, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, #16369 Jingshi Road, Jinan 250011, China
1 shared publication He Wen
Department of Dermatology, Qilu Hospital of Shandong University, Jinan, Shandong, China
1 shared publicationLin Zhang
Level Three Laboratory of Traditional Chinese Medicine Preparation of National Administration of Traditional Chinese Medicine, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, 250011, China
1 shared publicationMenghan Chen
1 shared publication
Latest Publications
- Open Access
- 29 May 2026
- Published by Springer Nature in Cell Death & Disease
PHF20 stabilizes the GAS7-F-actin axis to drive DNA damage repair and chemoresistance in cutaneous squamous cell carcinoma
Cutaneous squamous cell carcinoma (cSCC) is a common and aggressive skin cancer, with treatment options for advanced stages often limited by chemoresistance. Here, we observe a positive correlation between PHF20 expression and the malignancy and tumor grade of cSCC. Functional studies suggest that PHF20 promotes oncogenic phenotypes, including proliferation, invasion, and epithelial-mesenchymal transition. Notably, PHF20 depletion appears to sensitize cSCC cells to chemotherapeutic agents. Mechanistically, we show that PHF20 interacts with and promotes the ubiquitin-mediated degradation of GAS7. This downregulation of GAS7 is associated with nuclear F-actin assembly, a process that has been implicated in DNA damage repair (DDR). Consequently, PHF20 loss stabilizes GAS7, enhances nuclear F-actin assembly, and is accompanied by increased DNA damage accumulation. These in vitro findings were corroborated in vivo, where PHF20 knockdown suppressed tumor growth and increased DNA damage. Together, PHF20 may contribute to the regulation of DDR and chemotherapeutic response, highlighting its potential as a therapeutic target in poorly differentiated cSCC.
- 29 May 2026
- Published by Springer Nature in Cell Death & Disease
Open AccessPHF20 stabilizes the GAS7-F-actin axis to drive DNA damage repair and chemoresistance in cutaneous squamous cell carcinoma
Cutaneous squamous cell carcinoma (cSCC) is a common and aggressive skin cancer, with treatment options for advanced stages often limited by chemoresistance. Here, we observe a positive correlation between PHF20 expression and the malignancy and tumor grade of cSCC. Functional studies suggest that PHF20 promotes oncogenic phenotypes, including proliferation, invasion, and epithelial-mesenchymal transition. Notably, PHF20 depletion appears to sensitize cSCC cells to chemotherapeutic agents. Mechanistically, we show that PHF20 interacts with and promotes the ubiquitin-mediated degradation of GAS7. This downregulation of GAS7 is associated with nuclear F-actin assembly, a process that has been implicated in DNA damage repair (DDR). Consequently, PHF20 loss stabilizes GAS7, enhances nuclear F-actin assembly, and is accompanied by increased DNA damage accumulation. These in vitro findings were corroborated in vivo, where PHF20 knockdown suppressed tumor growth and increased DNA damage. Together, PHF20 may contribute to the regulation of DDR and chemotherapeutic response, highlighting its potential as a therapeutic target in poorly differentiated cSCC.
- 22 November 2024
- Published by Elsevier in Environmental Pollution
- Vol. 364 (Pt 2) , 125377
Pesticide avermectin B1a exerts cytotoxicity by blocking the interaction between mini-chromosome maintenance 6 protein (MCM6) and chromatin licensing and DNA replication factor 1 (CDT1)
- 22 November 2024
- Published by Elsevier in Environmental Pollution
- Vol. 364 (Pt 2) , 125377
Pesticide avermectin B1a exerts cytotoxicity by blocking the interaction between mini-chromosome maintenance 6 protein (MCM6) and chromatin licensing and DNA replication factor 1 (CDT1)